Clinical trial · Interventional
CEST in Low-grade Glioma Study
A Multi-institutional Observational Study of CEST Imaging in Low-grade Glioma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Low grade gliomas (LGGs) are malignant, infiltrative and incurable brain tumours that typically present in the younger population. This project proposes to use non-contrast metabolic "Saturation Transfer" (ST)-MRI to evaluate LGG tumour progression and aims to predict early changes in LGG. Early identification of LGG patients whose tumours will progress will permit early interventions. ST-MRI does not involve any intravenous injection of contrast and which acquires metabolic information not seen by standard MRI.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Low-grade Glioma | Low Grade Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Saturation Transfer (ST)-MRI | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- ST-MRI scans
- description
- All patients will undergo Saturation Transfer (ST)-MRI during their standard of care imaging visits (or within 14 days of their standard MRI).
- interventionNames
- Diagnostic Test: Saturation Transfer (ST)-MRI
Primary outcomes (1)
- measure
- The time-to-progression as measured by Saturation Transfer (ST)-MRI (based on a change in volume or parameter value of over 10%) relative to the time-to-progression as measured by standard MRI using RANO-LGG.
- timeFrame
- Up to 6 years, from date of initial (ST)-MRI scan until the date of progression
- description
- Time-to-progression refers to clinical progression of a low-grade glioma to a higher tumour grade.
Secondary outcomes (1)
- measure
- Accuracy of Saturation Transfer (ST)-MRI for detecting progression (based on a change in volume or parameter value of over 10%).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 12 Years
Show eligibility criteria text
Inclusion Criteria: 1. Be at least 12 years of age; 2. Diagnosed with: 1. Cohort A (pre-surgical): Suspected LGG (oligodendroglioma or astrocytoma), based on any combination of histological, molecular, radiological, and/or clinical findings; or 2. Cohort B (post-surgical): IDH1/2-mutant or IDH-wildtype (WT) low-grade glioma candidate for observation 3. No contraindications to MRI; 4. eGFR \> 30 ml/min; 5. No prior chemotherapy or radiation therapy; 6. No need for upfront treatment (surgery, chemotherapy, and/or radiation therapy) 7. Followed at either Sunnybrook Health Sciences Centre or at St Michael's Hospital Exclusion Criteria: 1. Need for upfront post-surgical treatment with either chemotherapy and/or radiation therapy 2. Pregnancy
References
Publications (0)
Data not yet available